(VTRS) Viatris - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US92556V1061
Stock: Prescription, Generic, Biosimilar, Complex, Injectables
Total Rating 55
Risk 53
Buy Signal 0.08
| Risk 5d forecast | |
|---|---|
| Volatility | 32.0% |
| Relative Tail Risk | -9.71% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.23 |
| Alpha | 32.68 |
| Character TTM | |
|---|---|
| Beta | 0.782 |
| Beta Downside | 1.113 |
| Drawdowns 3y | |
|---|---|
| Max DD | 45.02% |
| CAGR/Max DD | 0.42 |
EPS (Earnings per Share)
Revenue
Description: VTRS Viatris February 25, 2026
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company operating across four geographic segments-Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets-offering a broad portfolio that includes prescription brands, generics, complex generics, and biosimilars for therapeutic areas such as cardiovascular, CNS, oncology, and infectious diseases.
Recent data shows Viatris generated $13.2 billion in total revenue for FY 2023, with a 5.8 % year-over-year increase driven by strong generic drug demand in the United States and expanding biosimilar sales in Europe. The company’s R&D spend rose to $1.1 billion, reflecting a strategic focus on complex generics and next-generation biosimilars, while the global generic pharmaceuticals market is projected to grow at a CAGR of 7 % through 2028, supported by cost-containment pressures in major healthcare systems.
For deeper insights, consider reviewing ValueRay’s analyst coverage to complement your evaluation of Viatris’s growth prospects.
Headlines to watch out for
- Generic drug competition erodes Viatriss established product revenue
- Biosimilar pipeline approvals boost future sales growth
- Debt reduction efforts improve financial stability
- Regulatory scrutiny on drug pricing impacts profitability
- Global economic slowdown reduces pharmaceutical demand
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: -3.51b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.18 > 1.0 |
| NWC/Revenue: 14.87% < 20% (prev 25.38%; Δ -10.51% < -1%) |
| CFO/TA 0.06 > 3% & CFO 2.32b > Net Income -3.51b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.30 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.15b) vs 12m ago -3.41% < -2% |
| Gross Margin: 35.06% > 18% (prev 0.38%; Δ 3.47k% > 0.5%) |
| Asset Turnover: 36.34% > 50% (prev 35.52%; Δ 0.83% > 0%) |
| Interest Coverage Ratio: -6.78 > 6 (EBITDA TTM -395.4m / Interest Expense TTM 471.3m) |
Altman Z'' -0.35
| A: 0.06 (Total Current Assets 9.22b - Total Current Liabilities 7.09b) / Total Assets 37.19b |
| B: -0.01 (Retained Earnings -388.3m / Total Assets 37.19b) |
| C: -0.08 (EBIT TTM -3.19b / Avg Total Assets 39.35b) |
| D: -0.14 (Book Value of Equity -3.08b / Total Liabilities 22.48b) |
| Altman-Z'' Score: -0.35 = B |
Beneish M -3.17
| DSRI: 0.98 (Receivables 3.35b/3.52b, Revenue 14.30b/14.74b) |
| GMI: 1.09 (GM 35.06% / 38.15%) |
| AQI: 0.96 (AQ_t 0.67 / AQ_t-1 0.70) |
| SGI: 0.97 (Revenue 14.30b / 14.74b) |
| TATA: -0.16 (NI -3.51b - CFO 2.32b) / TA 37.19b) |
| Beneish M-Score: -3.17 (Cap -4..+1) = AA |
What is the price of VTRS shares?
As of March 20, 2026, the stock is trading at USD 13.50 with a total of 11,426,682 shares traded.
Over the past week, the price has changed by -2.17%, over one month by -14.80%, over three months by +14.13% and over the past year by +49.99%.
Over the past week, the price has changed by -2.17%, over one month by -14.80%, over three months by +14.13% and over the past year by +49.99%.
Is VTRS a buy, sell or hold?
Viatris has received a consensus analysts rating of 3.44.
Therefor, it is recommend to hold VTRS.
- StrongBuy: 2
- Buy: 1
- Hold: 5
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the VTRS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 15.5 | 14.8% |
| Analysts Target Price | 15.5 | 14.8% |
VTRS Fundamental Data Overview March 18, 2026
P/E Forward = 5.5066
P/S = 1.0881
P/B = 1.0574
P/EG = 0.0728
Revenue TTM = 14.30b USD
EBIT TTM = -3.19b USD
EBITDA TTM = -395.4m USD
Long Term Debt = 12.48b USD (from longTermDebt, last quarter)
Short Term Debt = 2.04b USD (from shortTermDebt, last quarter)
Debt = 14.70b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.35b USD (from netDebt column, last quarter)
Enterprise Value = 28.81b USD (15.56b + Debt 14.70b - CCE 1.45b)
Interest Coverage Ratio = -6.78 (Ebit TTM -3.19b / Interest Expense TTM 471.3m)
EV/FCF = 15.82x (Enterprise Value 28.81b / FCF TTM 1.82b)
FCF Yield = 6.32% (FCF TTM 1.82b / Enterprise Value 28.81b)
FCF Margin = 12.73% (FCF TTM 1.82b / Revenue TTM 14.30b)
Net Margin = -24.58% (Net Income TTM -3.51b / Revenue TTM 14.30b)
Gross Margin = 35.06% ((Revenue TTM 14.30b - Cost of Revenue TTM 9.29b) / Revenue TTM)
Gross Margin QoQ = 30.63% (prev 36.83%)
Tobins Q-Ratio = 0.77 (Enterprise Value 28.81b / Total Assets 37.19b)
Interest Expense / Debt = 0.81% (Interest Expense 119.6m / Debt 14.70b)
Taxrate = 21.0% (US default 21%)
NOPAT = -2.52b (EBIT -3.19b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.30 (Total Current Assets 9.22b / Total Current Liabilities 7.09b)
Debt / Equity = 1.00 (Debt 14.70b / totalStockholderEquity, last quarter 14.71b)
Debt / EBITDA = -33.77 (negative EBITDA) (Net Debt 13.35b / EBITDA -395.4m)
Debt / FCF = 7.34 (Net Debt 13.35b / FCF TTM 1.82b)
Total Stockholder Equity = 15.29b (last 4 quarters mean from totalStockholderEquity)
RoA = -8.93% (Net Income -3.51b / Total Assets 37.19b)
RoE = -22.99% (Net Income TTM -3.51b / Total Stockholder Equity 15.29b)
RoCE = -11.50% (EBIT -3.19b / Capital Employed (Equity 15.29b + L.T.Debt 12.48b))
RoIC = -8.51% (negative operating profit) (NOPAT -2.52b / Invested Capital 29.66b)
WACC = 4.84% (E(15.56b)/V(30.26b) * Re(8.80%) + D(14.70b)/V(30.26b) * Rd(0.81%) * (1-Tc(0.21)))
Discount Rate = 8.80% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.00%
[DCF] Terminal Value 85.21% ; FCFF base≈1.87b ; Y1≈1.69b ; Y5≈1.45b
[DCF] Fair Price = 26.38 (EV 43.72b - Net Debt 13.35b = Equity 30.37b / Shares 1.15b; r=5.90% [WACC]; 5y FCF grow -12.37% → 2.90% )
EPS Correlation: -79.25 | EPS CAGR: -12.24% | SUE: 0.86 | # QB: 3
Revenue Correlation: -75.54 | Revenue CAGR: -3.25% | SUE: 2.22 | # QB: 3
EPS next Quarter (2026-06-30): EPS=0.61 | Chg7d=-0.003 | Chg30d=-0.039 | Revisions Net=-2 | Analysts=7
EPS current Year (2026-12-31): EPS=2.44 | Chg7d=+0.003 | Chg30d=-0.028 | Revisions Net=+0 | Growth EPS=+4.0% | Growth Revenue=+2.1%
EPS next Year (2027-12-31): EPS=2.66 | Chg7d=-0.009 | Chg30d=-0.039 | Revisions Net=-1 | Growth EPS=+8.8% | Growth Revenue=+1.7%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
P/S = 1.0881
P/B = 1.0574
P/EG = 0.0728
Revenue TTM = 14.30b USD
EBIT TTM = -3.19b USD
EBITDA TTM = -395.4m USD
Long Term Debt = 12.48b USD (from longTermDebt, last quarter)
Short Term Debt = 2.04b USD (from shortTermDebt, last quarter)
Debt = 14.70b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.35b USD (from netDebt column, last quarter)
Enterprise Value = 28.81b USD (15.56b + Debt 14.70b - CCE 1.45b)
Interest Coverage Ratio = -6.78 (Ebit TTM -3.19b / Interest Expense TTM 471.3m)
EV/FCF = 15.82x (Enterprise Value 28.81b / FCF TTM 1.82b)
FCF Yield = 6.32% (FCF TTM 1.82b / Enterprise Value 28.81b)
FCF Margin = 12.73% (FCF TTM 1.82b / Revenue TTM 14.30b)
Net Margin = -24.58% (Net Income TTM -3.51b / Revenue TTM 14.30b)
Gross Margin = 35.06% ((Revenue TTM 14.30b - Cost of Revenue TTM 9.29b) / Revenue TTM)
Gross Margin QoQ = 30.63% (prev 36.83%)
Tobins Q-Ratio = 0.77 (Enterprise Value 28.81b / Total Assets 37.19b)
Interest Expense / Debt = 0.81% (Interest Expense 119.6m / Debt 14.70b)
Taxrate = 21.0% (US default 21%)
NOPAT = -2.52b (EBIT -3.19b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.30 (Total Current Assets 9.22b / Total Current Liabilities 7.09b)
Debt / Equity = 1.00 (Debt 14.70b / totalStockholderEquity, last quarter 14.71b)
Debt / EBITDA = -33.77 (negative EBITDA) (Net Debt 13.35b / EBITDA -395.4m)
Debt / FCF = 7.34 (Net Debt 13.35b / FCF TTM 1.82b)
Total Stockholder Equity = 15.29b (last 4 quarters mean from totalStockholderEquity)
RoA = -8.93% (Net Income -3.51b / Total Assets 37.19b)
RoE = -22.99% (Net Income TTM -3.51b / Total Stockholder Equity 15.29b)
RoCE = -11.50% (EBIT -3.19b / Capital Employed (Equity 15.29b + L.T.Debt 12.48b))
RoIC = -8.51% (negative operating profit) (NOPAT -2.52b / Invested Capital 29.66b)
WACC = 4.84% (E(15.56b)/V(30.26b) * Re(8.80%) + D(14.70b)/V(30.26b) * Rd(0.81%) * (1-Tc(0.21)))
Discount Rate = 8.80% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.00%
[DCF] Terminal Value 85.21% ; FCFF base≈1.87b ; Y1≈1.69b ; Y5≈1.45b
[DCF] Fair Price = 26.38 (EV 43.72b - Net Debt 13.35b = Equity 30.37b / Shares 1.15b; r=5.90% [WACC]; 5y FCF grow -12.37% → 2.90% )
EPS Correlation: -79.25 | EPS CAGR: -12.24% | SUE: 0.86 | # QB: 3
Revenue Correlation: -75.54 | Revenue CAGR: -3.25% | SUE: 2.22 | # QB: 3
EPS next Quarter (2026-06-30): EPS=0.61 | Chg7d=-0.003 | Chg30d=-0.039 | Revisions Net=-2 | Analysts=7
EPS current Year (2026-12-31): EPS=2.44 | Chg7d=+0.003 | Chg30d=-0.028 | Revisions Net=+0 | Growth EPS=+4.0% | Growth Revenue=+2.1%
EPS next Year (2027-12-31): EPS=2.66 | Chg7d=-0.009 | Chg30d=-0.039 | Revisions Net=-1 | Growth EPS=+8.8% | Growth Revenue=+1.7%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)